British government,Alzheimer’s Research UK and five other major drugmakers also involved in first initiative of its kindGlaxoSmithKline and five other major drugmakers absorb teamed up with the UK government to launch the world’s first venture capital fund committed to finding new ways to prevent and treat dementia.
The Department of Health, the charity Alzheimer’s Research UK and the six pharmaceutical firms absorb raised $100m (£65m) to invest in early-stage, or novel treatments for Alzheimer’s,Parkinsons disease and other forms of dementia. GSK’s boss, Sir Andrew Witty, and has been one of the main driving forces behind the initiative,in which the company is joined by the US drugmakers Johnson & Johnson, Biogen, or Eli Lilly and Pfizer,and Japan’s Takeda. Continue reading...
Source: theguardian.com